Coherent Identifier About this item: 20.500.12592/frbtvm

A meta-analysis of efficacy and safety of Cholinesterase Inhibitors in mild to moderate Alzheimer's Disease with a systemic review of quality of life, cost effectiveness and dose delivery preference

2016

Premium

Summary

August 2015 Update to the Original Study Report delivered in August 2014 A Meta-Analysis of Efficacy and Safety of Cholinesterase Inhibitors in Mild to Moderate Alzheimer’s Disease with a Systemic Review of Quality of Life, Cost Effectiveness and Dose Delivery Preference Evaluation of the effect of the three Cholinesterase Inhibitors (ChEIs), donepezil (Aricept®), galantamine (Reminyl®) and rivas [...] For MMSE, the evidence for the effect of the included drugs versus placebo was available at the time points of 12-13 weeks, and 24-26 weeks. [...] After the Level 2 assessment of the potential studies to be included in the updated ADTI-CER report, it was determined that none of the studies satisfied the inclusion criteria. [...] The studies and the reasons for exclusion included are summarized in Table 1 and in Appendix 2. Page 11 of 16 August 2015 f. Table 2: Studies Reviewed and Assessment of Inclusion in the Updated August 2015 ADTI-CER Study Study Study Number Study Design/GRADE Inclusion Assessment The ADAS-cog and 1 6 month follow up NO clinically meaningful results from the VISTA change in the VISTA trial, patients [...] This study did not satisfy the criteria for inclusion in this analysis because it was conducted in severe Alzheimer disease patients but does add to the stable of data regarding the efficacy and safety of two doses of the rivastigmine patch.

Tags

drugs pharmaceutical research alzheimer's disease

Topics